Alpha-Synuclein: Adding Precision to Neurodegenerative Testing
In this episode of Clinical Lab Chat, CLP’s Director of Business Intelligence, Chris Wolski, discusses the how and why of making precise clinical diagnosis of neurodegenerative diseases with Russ Lebovitz, MD, PhD, co-founder and CEO of Amprion.
Among the topics they discuss:
- The critical importance of making accurate diagnoses of neurodegenerative diseases
- Why alpha-synuclein is an accurate biomarker for a number of degenerative diseases, including Alzheimer’s
- How adding neurodegenerative testing to the routine diagnostic menu would benefit patients and their caregivers
- Why we’re entering a neurological healthcare “golden age”
2025-01-06
24 min
Available Results
Generated results are saved to the knowledge database for reuse and search.
No generated results are available for this episode yet.
Extract Knowledge
Pick what you want extracted first. Model, scope, and chapter options appear after a template is selected.
Generated results for public episodes are saved to the knowledge database so they can be reused and searched later.
Transcript
No transcript is available for this episode yet.
Sign in to generate a transcript for review.
Sign in
Chapters
No chapters available.